Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1298943 | 1.00 | PRMT1 (0.63) | PRMT1ADRA1AMAPK1ITGB3ITGA2B | |
| SCHEMBL5536342 | 1.00 | PRMT1 (0.63) | PRMT1ADRA1AMAPK1ITGB3ITGA2B | |
| SCHEMBL5536799 | 1.00 | PRMT1 (0.63) | PRMT1ADRA1AMAPK1ITGB3ITGA2B | |
| SCHEMBL5531367 | 1.00 | PRMT1 (0.63) | PRMT1ADRA1AMAPK1ITGB3ITGA2B | |
| SCHEMBL5538332 | 1.00 | PRMT1 (0.63) | PRMT1ADRA1AMAPK1ITGB3ITGA2B | |
| SCHEMBL5533323 | 1.00 | PRMT1 (0.63) | PRMT1ADRA1AMAPK1ITGB3ITGA2B | |
| SCHEMBL5535532 | 1.00 | PRMT1 (0.63) | PRMT1ADRA1AMAPK1ITGB3ITGA2B | |
| SCHEMBL5533492 | 1.00 | PRMT1 (0.63) | PRMT1ADRA1AMAPK1ITGB3ITGA2B | |
| SCHEMBL1360401 | 1.00 | PRMT1 (0.63) | PRMT1ADRA1AMAPK1ITGB3ITGA2B | |
| SCHEMBL5535128 | 1.00 | PRMT1 (0.63) | PRMT1ADRA1AMAPK1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4230299-A | — | — | None | — | — | JP | disclosed |
| US-11739122-B2 | Glycopeptide antibiotic compounds, methods for producing the same, and uses thereof | ACADEMIA SINICA (TW) | 2023-08-29 | — | — | US | disclosed |
| US-20200291071-A1 | GLYCOPEPTIDE COMPOUNDS, METHODS FOR PRODUCING THE SAME, AND USES THEREOF | ACADEMIA SINICA (TW) | 2020-09-17 | — | — | US | disclosed |
| US-20070044831-A1 | Electrolyte composition and dye-sensitized solar cell | NATIONAL UNIVERSITY CORPORATION KYUSHU INSTITUTE OF TECHNOLOGY (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-0454651-B1 | Novel platelet-aggregation inhibitors | MONSANTO CO (US) | 1999-07-28 | — | — | EP | disclosed |
| US-5817756-A | USING A MODIFIED DI- OR TRI-PEPTIDES | SCIOS INC. (US) | 1998-10-06 | — | — | US | disclosed |
| US-5614539-A | ANTICOAGULANTS | G. D. SEARLE & CO. (US) | 1997-03-25 | — | — | US | disclosed |
| US-5583020-A | IONIZATION; DRUG DELIVERY | RIBOZYME PHARMACEUTICALS, INC. (US) | 1996-12-10 | — | — | US | disclosed |
| EP-0716661-A1 | PSEUDO- AND NON-PEPTIDE BRADYKININ RECEPTOR ANTAGONISTS | SCIOS NOVA INC. (US) | 1996-06-19 | — | — | EP | disclosed |
| EP-0669926-A1 | PERMEABILITY ENHANCERS FOR IONIC THERAPEUTIC POLYMERS | RIBOZYME PHARMACEUTICALS, INC. (US) | 1995-09-06 | — | — | EP | disclosed |
| WO-1993011759-A1 | ANTITHROMBOTIC DIAMINOALKANOIC ACID DERIVATIVES | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1993-06-24 | — | — | WO | disclosed |
| JP-H04230299-A | NEW PLATELET AGGREGATION INHIBITOR | MONSANTO CO | 1992-08-19 | — | — | JP | disclosed |
| US-5091396-A | Guanidinoalkanoylaspartylpyridine derivatives; anticoagulants | MONSANTO CO. (US) | 1992-02-25 | — | — | US | disclosed |
| EP-0462960-A1 | Novel platelet-aggregation inhibitor | MONSANTO COMPANY (US) | 1991-12-27 | — | — | EP | disclosed |
| EP-0454651-A2 | Novel platelet-aggregation inhibitors | MONSANTO COMPANY (US) | 1991-10-30 | — | — | EP | disclosed |
| US-5053393-A | 8-guanidinooctanoyl-asparty-phenylalanine; cardiovascular disorders | MONSANTO COMPANY (US) | 1991-10-01 | — | — | US | disclosed |
| US-5037808-A | Indolyl platelet-aggregation inhibitors | MONSANTO CO. (US) | 1991-08-06 | — | — | US | disclosed |
| US-4992463-A | Thienyl peptide mimetic compounds which are useful in inhibiting platelet aggregation | MONSANTO COMPANY (US) | 1991-02-12 | — | — | US | disclosed |
| EP-0352249-A1 | Novel platelet-aggregation inhibitors | Monsanto Company (US) | 1990-01-24 | — | — | EP | disclosed |
| US-4879313-A | ANTICOAGULANTS | MOSANTO COMPANY (US) | 1989-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291071-A1 | GLYCOPEPTIDE COMPOUNDS, METHODS FOR PRODUCING THE SAME, AND USES THEREOF | B3GAT3, MGAM, GALNT14 | PRMT1 3225/4885ADRA1A 4377/4885MAPK1 3577/4885 |
| US-11739122-B2 | Glycopeptide antibiotic compounds, methods for producing the same, and uses thereof | NGLY1, NRDC, MGAT3 | PRMT1 1023/4885ADRA1A 3767/4885MAPK1 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.